Vascular Endothelial Growth Factor Receptor 3 (FLT4) Antibody (Biotin)

Este producto es parte de FLT4 -  fms related receptor tyrosine kinase 4
Product Graph
169€ (20 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Vascular Endothelial Growth Factor Receptor 3 (FLT4) Antibody (Biotin)
category
Primary Antibodies
provider
Abbexa
reference
abx315380
tested applications
ELISA

Description

FLT4 Antibody (Biotin) is a Rabbit Polyclonal against FLT4 conjugated to Biotin.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Vascular Endothelial Growth Factor Receptor 3 (FLT4)
Host
Rabbit
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Biotin
Isotype
IgG
Purity
> 95%
Purification
Purified by Protein G.
Size 1
20 µg
Size 2
50 µg
Size 3
100 µg
Size 4
200 µg
Size 5
1 mg
Form
Liquid
Tested Applications
ELISA
Buffer
0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P35916
Gene ID
2324
NCBI Accession
NP_002011.2, NM_002020.4, NP_891555.2, NM_182925.4
OMIM
136352
Alias
PCL,CHTD7,FLT-4,FLT41,LMPH1A,LMPHM1,VEGFR3,VEGFR-3,Tyrosine-protein kinase receptor FLT4,Fms-like tyrosine kinase 4,Vascular endothelial growth factor receptor 3
Background
Antibody anti-FLT4
Status
RUO

Descripción

Fms related receptor tyrosine kinase 4 (FLT4) FLT4, also known as vascular endothelial growth factor receptor 3 (VEGFR3), is a receptor tyrosine kinase critical for the regulation of lymphangiogenesis, the formation of lymphatic vessels. Structurally, FLT4 comprises an extracellular domain with seven immunoglobulin-like loops, a single transmembrane domain, and an intracellular tyrosine kinase domain. FLT4 binds VEGF-C and VEGF-D ligands, leading to receptor dimerization and activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades. These pathways are essential for lymphatic endothelial cell proliferation, migration, and survival. FLT4 is predominantly expressed in lymphatic endothelial cells, where it plays a pivotal role in maintaining lymphatic vessel integrity and fluid homeostasis. Dysregulation of FLT4 has been linked to lymphedema, a condition characterized by lymphatic fluid accumulation, and its overexpression has been implicated in cancer progression, where it promotes tumor lymphangiogenesis and metastasis. FLT4 is a promising therapeutic target for modulating lymphatic function in both pathological and developmental contexts.

Related Products

EH0729

Human FLT4 (Vascular endothelial growth factor receptor 3) ELISA Kit

Ver Producto
EM0206

Mouse VEGFR3/FLT4 (Vascular Endothelial Cell Growth Factor Receptor 3) ELISA Kit

Ver Producto
ER0238

Rat Flt4 (Vascular endothelial growth factor receptor 3) ELISA Kit

Ver Producto